Primary Category:
Treatment Protocols
Disease Category:
Molecular Profiling
Status:
Open
Phase 2 Study of Nivolumab and BMS-986016 (Relatlimab) in Patients with LAG-3+ Tumors with Mismatch Repair Deficiency (MMR-d) after Progression on Anti-PD-1/PD-L1 Therapy
(See required screening study ECOG-ACRIN EAY131)
EAY131-Z1M is reopened to accrual with the implementation of Addendum 30, effective February 23, 2022.
NCT#02465060
